Suppr超能文献

高血糖与药物性颌骨坏死(MRONJ)之间的关联。

Association between Hyperglycemia and Medication-Related Osteonecrosis of the Jaw (MRONJ).

作者信息

Kammerhofer Gabor, Vegh Daniel, Bányai Dorottya, Végh Ádám, Joob-Fancsaly Arpad, Hermann Peter, Geczi Zoltan, Hegedus Tamas, Somogyi Kata Sara, Bencze Bulcsú, Biczó Zita, Juhász Donát Huba, Zaborszky Péter, Ujpál Márta, Vaszilkó Mihály Tamás, Németh Zsolt

机构信息

Department of Oromaxillofacial Surgery and Stomatology, Semmelweis University, 1088 Budapest, Hungary.

Diabetes-Dental Working Group, Semmelweis University, 1088 Budapest, Hungary.

出版信息

J Clin Med. 2023 Apr 19;12(8):2976. doi: 10.3390/jcm12082976.

Abstract

BACKGROUND

Medication-related osteonecrosis of the jaw (MRONJ) is a type of jawbone necrosis caused by the use of drugs for some types of cancer and osteoporosis. The current study aimed to evaluate the associations between hyperglycemia and the development of medication-related osteonecrosis of the jaw.

METHODS

Our research group investigated data collected between 1 January 2019 and 31 December 2020. A total of 260 patients were selected from the Inpatient Care Unit, Department of Oromaxillofacial Surgery and Stomatology, Semmelweis University. Fasting glucose data were used and included in the study.

RESULTS

Approximately 40% of the necrosis group and 21% of the control group presented with hyperglycemia. There was a significant association between hyperglycemia and MRONJ ( < 0.05, = 0.003). Vascular anomaly and immune dysfunction caused by hyperglycemia can lead to necrosis after tooth extraction. Necrosis is more common in the mandible (75.0%) and in the case of parenteral antiresorptive treatment (intravenous Zoledronate and subcutaneous Denosumab). Hyperglycemia is a more relevant risk factor than bad oral habits (26.7%).

CONCLUSIONS

Ischemia is a complication of abnormal glucose levels, a possible risk factor for necrosis development. Hence, uncontrolled or poorly regulated plasma glucose levels can significantly increase the risk of jawbone necrosis after invasive dental or oral surgical interventions.

摘要

背景

药物性颌骨坏死(MRONJ)是一种因使用某些治疗癌症和骨质疏松症的药物而导致的颌骨坏死类型。本研究旨在评估高血糖与药物性颌骨坏死发生之间的关联。

方法

我们的研究小组调查了2019年1月1日至2020年12月31日期间收集的数据。从塞梅尔维斯大学口腔颌面外科和口腔医学住院护理单元选取了260例患者。使用空腹血糖数据并纳入研究。

结果

坏死组约40%的患者和对照组21%的患者出现高血糖。高血糖与药物性颌骨坏死之间存在显著关联(<0.05,=0.003)。高血糖引起的血管异常和免疫功能障碍可导致拔牙后坏死。坏死在下颌骨中更常见(75.0%),且在接受胃肠外抗吸收治疗(静脉注射唑来膦酸和皮下注射地诺单抗)的情况下更易发生。高血糖是比不良口腔习惯(26.7%)更相关的危险因素。

结论

缺血是血糖水平异常的一种并发症,是坏死发生的一个可能危险因素。因此,血浆葡萄糖水平不受控制或调节不佳会显著增加侵入性牙科或口腔外科手术后颌骨坏死的风险。

相似文献

1
Association between Hyperglycemia and Medication-Related Osteonecrosis of the Jaw (MRONJ).
J Clin Med. 2023 Apr 19;12(8):2976. doi: 10.3390/jcm12082976.
3
Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center.
Saudi Dent J. 2022 Sep;34(6):479-484. doi: 10.1016/j.sdentj.2022.06.004. Epub 2022 Jun 20.
4
Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
Int J Implant Dent. 2021 May 14;7(1):47. doi: 10.1186/s40729-021-00323-0.
5
Risk factors of medication-related osteonecrosis of the jaw: A clinical investigation.
J Stomatol Oral Maxillofac Surg. 2024 Dec;125(6):101791. doi: 10.1016/j.jormas.2024.101791. Epub 2024 Feb 4.
7
Emerging antiresorptive medications and their potential implications for dental surgeries.
J Am Dent Assoc. 2022 Jul;153(7):649-658. doi: 10.1016/j.adaj.2021.12.008. Epub 2022 Mar 8.
9
The effect of drug holiday on preventing medication-related osteonecrosis of the jaw in osteoporotic rat model.
J Orthop Translat. 2023 Jan 10;39:55-62. doi: 10.1016/j.jot.2022.12.006. eCollection 2023 Mar.
10
[Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Wien Med Wochenschr. 2016 Feb;166(1-2):68-74. doi: 10.1007/s10354-016-0437-2.

引用本文的文献

3
Antiresorptive Versus Anabolic Therapy in Managing Osteoporosis in People with Type 1 and Type 2 Diabetes.
JBMR Plus. 2023 Oct 29;7(11):e10838. doi: 10.1002/jbm4.10838. eCollection 2023 Nov.
4
Are medication-induced salivary changes the culprit of osteonecrosis of the jaw? A systematic review.
Front Med (Lausanne). 2023 Aug 31;10:1164051. doi: 10.3389/fmed.2023.1164051. eCollection 2023.

本文引用的文献

1
Medication-related osteonecrosis of the jaw triggered by endodontic failure in oncologic patients.
Oral Dis. 2023 Oct;29(7):2799-2805. doi: 10.1111/odi.14449. Epub 2022 Dec 15.
2
Point-of-care HbA1c Measurements in Oral Cancer and Control Patients in Hungary.
In Vivo. 2022 Sep-Oct;36(5):2248-2254. doi: 10.21873/invivo.12952.
5
American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update.
J Oral Maxillofac Surg. 2022 May;80(5):920-943. doi: 10.1016/j.joms.2022.02.008. Epub 2022 Feb 21.
6
Medication-related osteonecrosis of the jaw: Prosthodontic considerations.
Jpn Dent Sci Rev. 2022 Nov;58:9-12. doi: 10.1016/j.jdsr.2021.11.005. Epub 2021 Dec 18.
8
9
Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results.
Cancers (Basel). 2021 Nov 24;13(23):5896. doi: 10.3390/cancers13235896.
10
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab.
Clin Oral Investig. 2022 Mar;26(3):2839-2852. doi: 10.1007/s00784-021-04261-4. Epub 2021 Nov 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验